- Home
- ANDE vs ELVN Comparison
ANDE vs ELVN Comparison
Compare ANDE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANDE
- ELVN
- Stock Information
- Founded
- ANDE 1947
- ELVN 2016
- Country
- ANDE United States
- ELVN United States
- Employees
- ANDE N/A
- ELVN N/A
- Industry
- ANDE Farming/Seeds/Milling
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- ANDE Industrials
- ELVN Health Care
- Exchange
- ANDE Nasdaq
- ELVN Nasdaq
- Market Cap
- ANDE 1.3B
- ELVN 1.2B
- IPO Year
- ANDE N/A
- ELVN 2020
- Fundamental
- Price
- ANDE $37.11
- ELVN $22.00
- Analyst Decision
- ANDE Buy
- ELVN Strong Buy
- Analyst Count
- ANDE 3
- ELVN 5
- Target Price
- ANDE $51.67
- ELVN $41.20
- AVG Volume (30 Days)
- ANDE 265.5K
- ELVN 545.5K
- Earning Date
- ANDE 08-04-2025
- ELVN 08-12-2025
- Dividend Yield
- ANDE 2.12%
- ELVN N/A
- EPS Growth
- ANDE N/A
- ELVN N/A
- EPS
- ANDE 3.17
- ELVN N/A
- Revenue
- ANDE $11,198,429,000.00
- ELVN N/A
- Revenue This Year
- ANDE $3.46
- ELVN N/A
- Revenue Next Year
- ANDE $5.01
- ELVN N/A
- P/E Ratio
- ANDE $11.62
- ELVN N/A
- Revenue Growth
- ANDE N/A
- ELVN N/A
- 52 Week Low
- ANDE $31.03
- ELVN $13.30
- 52 Week High
- ANDE $55.52
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- ANDE 47.60
- ELVN 51.35
- Support Level
- ANDE $35.77
- ELVN $21.12
- Resistance Level
- ANDE $37.29
- ELVN $24.38
- Average True Range (ATR)
- ANDE 1.09
- ELVN 1.56
- MACD
- ANDE -0.24
- ELVN -0.01
- Stochastic Oscillator
- ANDE 24.85
- ELVN 43.60
About ANDE Andersons Inc. (The)
Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.